24
Participants
Start Date
March 8, 2019
Primary Completion Date
March 31, 2026
Study Completion Date
December 31, 2026
[18F]GE-226
\[18F\]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
RECRUITING
Imperial College Healthcare NHS Trust, London
Collaborators (1)
Medical Research Council
OTHER_GOV
University of Cambridge
OTHER
Imperial College London
OTHER